<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article115</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/DELIVER" style="display:block; margin-bottom:10px;">DELIVER Original</a></li>
<h2><strong>DELIVER</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does dapagliflozin reduce the composite risk of worsening heart failure or cardiovascular death among patients with heart failure and a left ventricular ejection fraction of more than 40%?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Phase 3, international, multicenter, parallel-group, event-driven, randomized, placebo-controlled trial<br/>
- N=6,263 patients with heart failure and ejection fraction &gt;40%<br/>
- Intervention: Dapagliflozin 10 mg once daily (n=3,131)<br/>
- Placebo plus usual therapy (n=3,132)<br/>
- Median follow-up: 2.3 years<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Patients aged â‰¥40 years with heart failure and left ventricular ejection fraction of more than 40%<br/>
- Included patients with stabilized heart failure, with or without type 2 diabetes mellitus<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Randomly assigned to dapagliflozin 10 mg once daily or matching placebo, along with their usual therapy<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary: Composite of worsening heart failure or cardiovascular death<br/>
- Secondary: Total number of heart failure events and cardiovascular deaths; change in total symptom score on the Kansas City Cardiomyopathy Questionnaire; cardiovascular death; death from any cause<br/>
- Safety: Incidence of adverse events<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Specific inclusion and exclusion criteria may limit generalizability.<br/>
- Less than 5% of enrolled patients were Black, and while proportional on a regional basis, it is unclear how these findings may apply globally.<br/>
- Owing to the COVID-19 pandemic, completion of the 8-month symptom assessment was limited.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Supported by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full trial details and protocol information are available in the New England Journal of Medicine, published August 27, 2022.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
